Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $381K rose 1.1% year over year, behind the +7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.3% from the prior quarter. Over 3 fiscal years it compounded at +47.7% a year.

Context

  • Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.1% toward the trailing-twelve-month pace of +7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$381K-1.3% QoQ
Last fiscal yearDec 2025
$1.51M+37.4% YoY
LTMJun 2026
$1.52M+7.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.1%——
1 year+37.4%——
3-year CAGR+47.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.51M USD
Year-over-year change
+37.4%
4-year CAGR
+38.9%

Depreciation & Amortization vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.1% is the 3rd highest of 6, against a peer median of -28.6%.
  • Depreciation & amortization amounts to 0.1% of revenue for MDGL, versus a peer median of 36.6%.
MDGL Competitors
Depreciation & Amortization for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$2.16M USD-28.6%-14.3%10.8%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.52M USD+7.1%+47.7%0.1%
VKTXViking Therapeutics, Inc.LTM Jun 2026$450K USD+7.1%+14.0%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$244K USD+38.6%+190.2%3.4%
ALTAltimmune, Inc.LTM Mar 2026$106K USD-33.8%-39.0%294.4%
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 USD———
Peer median (excluding MDGL) —-28.6%+14.0%36.6%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.